C4 Therapeutics, Inc.
CCCC
NASDAQ·Healthcare·Biotechnology·Mkt cap $415.7M
$3.76
▲ +0.53%
P/E
-3.76
Mkt Cap
$415.7M
52-Wk Range
$1.69–$5.17
52-Week Range
$1.69 - $5.17
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 38.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary protein degradation technology (MonoDAC and BiDAC platforms)
- Strategic partnerships with pharmaceutical leaders (Roche, Biogen, Calico)
- Oral bioavailability of drug candidates
- Diverse pipeline targeting multiple cancer types and disease indications
Bear Case
1 risk
- High volatility (beta 2.9). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Clinical trial progression of CFT7455 in hematologic malignancies
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+4.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CCCC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$0.18 vs -$0.23 consensus (+20.5% surprise). Revenue of $6.6M vs $4.0M expected (+66.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.5%
Revenue trend · last 8Q
—
—
+138%
-46%
-27%
+113%
-15%
+3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$15.4M
$5.2M
$7.2M
$6.5M
$11.2M
$11.0M
$6.2M
$6.6M
Margins · last 8Q
Gross
100.0%
Operating
—
Profit
-355.9%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CCCC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related